Thalassemia highlights at ASH 2023: novel therapies, trial updates & the value of precision medicine

Thalassemia highlights at ASH 2023: novel therapies, trial updates & the value of precision medicineПодробнее

The current landscape of treatment for HR-MDS: an update from ASH 2023Подробнее

Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being exploredПодробнее

Overview of Novel Thalassemia TreatmentsПодробнее

Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and moreПодробнее

Thalassemia: Alpha & Beta-Thalassemias, Genetics, Pathophysiology, Diagnosis & Treatment, AnimationПодробнее

SCD highlights at ASH 2023: disease pathogenesis, ongoing clinical trials & novel gene therapiesПодробнее

Update on the ENERGIZE trial of mitapivat in NTD alpha- and beta-thalassemiaПодробнее

Overview: Novel Therapies in ThalassemiaПодробнее

A research update in Richter's transformation from ASH 2023Подробнее

Symposium | Targeted therapies for classic Hodgkin lymphomaПодробнее

Recent updates from the MajesTEC-4 trialПодробнее

Precision medicine, genomics and immunotherapies at ASH 2017Подробнее

ASH News TV 2023: Press BriefingsПодробнее

ASH News TV 2023: E. Donnall Thomas Lecture and PrizeПодробнее

RUBY & EdiTHAL trials: evaluating the safety and efficacy of EDIT-301 in SCD & thalassemiaПодробнее

The Highlight of Thalassemia by Prof. Vip ViprakasitПодробнее

What were the results of the DETERMINATION Trial presented at ASCO and EHA?Подробнее